Martina Caiazza

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9002795/martina-caiazza-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47 papers 242 9 h-index g-index

56 477 ext. papers ext. citations avg, IF 13 g-index

L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 47 | Multimodality Imaging in Cardiomyopathies with Hypertrophic Phenotypes <i>Journal of Clinical Medicine</i> , 2022 , 11, | 5.1 | 3 |
| 46 | The Risk of Sudden Unexpected Cardiac Death in Children: Epidemiology, Clinical Causes, and Prevention. <i>Heart Failure Clinics</i> , 2022 , 18, 115-123 | 3.3 | 4 |
| 45 | The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022 , 18, 61-72 | 3.3 | 1 |
| 44 | Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. <i>Heart Failure Clinics</i> , 2022 , 18, 31-37 | 3.3 | 4 |
| 43 | Cardiovascular Involvement in mtDNA Disease: Diagnosis, Management, and Therapeutic Options. <i>Heart Failure Clinics</i> , 2022 , 18, 51-60 | 3.3 | 3 |
| 42 | Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. <i>Heart Failure Clinics</i> , 2022 , 18, 39-49 | 3.3 | 4 |
| 41 | Clinical Manifestations of 22q11.2 Deletion Syndrome. <i>Heart Failure Clinics</i> , 2022 , 18, 155-164 | 3.3 | 4 |
| 40 | Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022 , 18, 73-87 | 3.3 | 3 |
| 39 | The Heart Muscle and Valve Involvement in Marfan Syndrome, Loeys-Dietz Syndromes, and Collagenopathies. <i>Heart Failure Clinics</i> , 2022 , 18, 165-175 | 3.3 | 1 |
| 38 | Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. <i>Neurology International</i> , 2022 , 12, 102-108 | О | |
| 37 | Clinical and Molecular Characteristics of Patients with PLN R14del Cardiomyopathy: State-of-the-Art Review. <i>Neurology International</i> , 2022 , 12, 112-121 | 0 | |
| 36 | Pancarditis as the Clinical Presentation of Eosinophilic Granulomatosis with Polyangiitis: A Multimodality Approach to Diagnosis. <i>Neurology International</i> , 2022 , 12, 133-141 | О | 0 |
| 35 | Modified Body Mass Index as a Novel Nutritional and Prognostic Marker in Patients with Cardiac Amyloidosis. <i>Neurology International</i> , 2022 , 12, 185-197 | О | O |
| 34 | Thoracic Aortic Dilation: Implications for Physical Activity and Sport Participation. <i>Diagnostics</i> , 2022 , 12, 1392 | 3.8 | 1 |
| 33 | Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis <i>Journal of Cardiovascular Echography</i> , 2021 , 31, 157-164 | 0.6 | 1 |
| 32 | Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. <i>Diagnostics</i> , 2021 , 11, | 3.8 | 3 |
| 31 | Imaging the "Hot Phase" of a Familiar Left-Dominant Arrhythmogenic Cardiomyopathy <i>Genes</i> , 2021 , 12, | 4.2 | 1 |

| 30 | MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. <i>Neurology International</i> , 2021 , 11, 230-254 | O | |
|----|--|-------------------|----|
| 29 | Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. <i>Future Cardiology</i> , 2021 , 17, 647-654 | 1.3 | 5 |
| 28 | Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. <i>Heart Failure Clinics</i> , 2021 , 17, 303-37 | 13 ^{3.3} | 4 |
| 27 | Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. <i>Pediatric Cardiology</i> , 2021 , 42, 1133-1140 | 2.1 | 2 |
| 26 | Molecular Epidemiology of Mitochondrial Cardiomyopathy: A Search Among Mitochondrial and Nuclear Genes. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 5 |
| 25 | Troponin T Mutation as a Cause of Left Ventricular Systolic Dysfunction in a Young Patient with Previous Surgical Correction of Aortic Coarctation. <i>Biomolecules</i> , 2021 , 11, | 5.9 | 1 |
| 24 | Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18, | 4.6 | 17 |
| 23 | Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. <i>Frontiers in Pediatrics</i> , 2021 , 9, 632293 | 3.4 | 13 |
| 22 | Cardiac Amyloidosis: Diagnostic Tools for a Challenging Disease. <i>Neurology International</i> , 2021 , 11, 111 | -121 | |
| 21 | A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , | 3.9 | 6 |
| 20 | External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. <i>International Journal of Cardiology</i> , 2021 , 339, 99-101 | 3.2 | 4 |
| 19 | Advanced Heart Failure in Special Population-Pediatric Age. <i>Heart Failure Clinics</i> , 2021 , 17, 673-683 | 3.3 | 1 |
| 18 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. <i>PLoS ONE</i> , 2020 , 15, e0233050 | 3.7 | 8 |
| 17 | Genetic analysis resolves differential diagnosis of a familial syndromic dilated cardiomyopathy: A new case of Alstr syndrome. <i>Molecular Genetics & amp; Genomic Medicine</i> , 2020 , 8, e1260 | 2.3 | 11 |
| 16 | Yield and clinical significance of genetic screening in elite and amateur athletes. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320934265 | 3.9 | 16 |
| 15 | Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria. <i>New England Journal of Medicine</i> , 2020 , 382, 835-844 | 59.2 | 10 |
| 14 | Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1906-1908 | 3.9 | 10 |
| 13 | Unexplained sudden cardiac arrest in children: clinical and genetic characteristics of survivors. European Journal of Preventive Cardiology, 2020, 2047487320940863 | 3.9 | 11 |

| 12 | The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 7 |
|----|--|-----|----|
| 11 | Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 18 |
| 10 | Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy. <i>Genes</i> , 2020 , 11, | 4.2 | 9 |
| 9 | Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17, | 4.6 | 8 |
| 8 | Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020 , 299, 186-191 | 3.2 | 32 |
| 7 | Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome. <i>Cardiology in the Young</i> , 2020 , 30, 663-667 | 1 | 5 |
| 6 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 2020 , 15, e0233050 | | |
| 5 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 2020 , 15, e0233050 | | |
| 4 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 2020 , 15, e0233050 | | |
| 3 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 2020 , 15, e0233050 | | |
| 2 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 2020 , 15, e0233050 | | |
| 1 | Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 2020 , 15, e0233050 | | |